Advancing covalent biologics to improve the treatment of cancer and other serious diseases
Enlaza is a San Diego, CA-based biotech developing novel technology for covalent protein targeting, a heretofore untapped opportunity. Similar to the manner in which covalent small molecule inhibitors offer a means to irreversibly bind the target, Enlaza is developing a suite of target-locking biologics that can be modularly- and irreversibly linked to a variety of effector molecules. Enlaza is building a pipeline of potential first-in-class covalent biologics with an initial focus in oncology.
